From early development to old age, cell death is a part of life. Without enough of a critical type of cell death known as ...

The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating ...

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make a cancer-targeting protein complex more stable, opening doors to better ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later ...

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...